Efficacy of treatments tested in COVID-19 patients with cardiovascular disease. A meta-analysis

Perfusion. 2023 Mar;38(2):373-383. doi: 10.1177/02676591211056559. Epub 2022 Feb 27.


Background: The COVID-19 pandemic has spread globally infecting and killing millions. Those with cardiovascular disease (CVD) are at higher risk of increased disease severity and mortality. We performed a systematic review and meta-analysis to estimate the rate of in-hospital mortality following different treatments on COVID-19 in patients with CVD.

Methods: Pertinent articles were identified from the PubMed, Google Scholar, Ovid MEDLINE, and Ovid EMBASE databases. This study protocol was registered under PROSPERO with the identifier CRD42020183057.

Results: Of the 1673 papers scrutinized, 46 were included in the review. Of the 2553 patients (mean age 63.9 ± 2.7 years/o; 57.2% male), the most frequent CVDs were coronary artery disease (9.09%) and peripheral arterial disease (5.4%) and the most frequent cardiovascular risk factors were hypertension (86.7%) and diabetes (23.7%). Most patients were on multiple treatments. 14 COVID-19 treatments were compared with controls. The pooled event rate for in-hospital mortality was 20% (95% confidence interval (CI): 11-33%); certain heterogeneity was observed across studies.

Conclusions: COVID-19 is associated with a high in-hospital mortality rate in patients with CVD. This study shows that previous CVD determines mortality, regardless of the type of COVID-19 administered therapy. Treatments for at-risk patients should be administered carefully and monitored closely until further data are available.

Keywords: COVID-19; cardiovascular disease; comorbidity; therapy.

Publication types

  • Systematic Review
  • Meta-Analysis

MeSH terms

  • Aged
  • COVID-19* / complications
  • Cardiovascular Diseases* / complications
  • Cardiovascular Diseases* / epidemiology
  • Female
  • Hospital Mortality
  • Humans
  • Hypertension*
  • Male
  • Middle Aged
  • Pandemics